No recent news coverage impacting the business model or operations was identified.

The company’s management team has extensive experience and a broad network that may provide access to attractive business combination opportunities. The SPAC structure offers potential advantages to target companies, including price certainty and faster access to public markets. The company’s capital in the Trust Account is secured and invested conservatively, preserving value for shareholders. The management’s operational expertise may support value creation post-business combination.

The company’s liquidity outside the Trust Account is limited, with a current ratio of 0.03 as of June 30, 2026, indicating potential constraints in covering short-term liabilities without the Trust Account. The company has no operations or full-time employees, relying on management’s discretionary time, which may limit execution capacity. The success of the business model depends on identifying and completing a suitable business combination within the prescribed timeframe, with risks including market conditions and regulatory approvals. Failure to complete a business combination within the combination period would lead to liquidation and return of funds to shareholders, with warrants and rights expiring worthless.

As a SPAC, Crown Reserve Acquisition Corp. I’s competitive strengths lie in its experienced management team with deep expertise in technology, financial services, healthcare technology, and consumer businesses. The team’s broad network across private equity, hedge funds, investment banks, and family offices provides access to proprietary deal flow and investment opportunities. The management’s operational and capital markets experience supports the identification, evaluation, and execution of business combinations. The SPAC structure offers advantages such as price certainty, speed of execution, and access to public capital markets for target companies, which can be leveraged by the management team’s expertise and relationships.

• Business Combination Completion Risk: The company must complete a business combination within 12 months from IPO closing, extendable to 15 months upon signing a definitive agreement. Failure to do so will result in liquidation and return of funds to shareholders, with warrants and rights expiring worthless.
• Liquidity Risk: As of June 30, 2026, the company’s current assets are significantly lower than current liabilities outside the Trust Account, with a current ratio of 0.03, indicating limited liquidity to cover short-term obligations without access to the Trust Account funds.
• Operational Risk: The company has no full-time employees and relies on management team members who are not obligated to devote specific hours, which may impact the ability to identify and complete a business combination efficiently.
• Market and Regulatory Risk: The ability to complete a business combination depends on market conditions, regulatory approvals, and meeting Nasdaq listing requirements, which may affect timing and feasibility.

• Crown Reserve Acquisition Corp. I is a blank check company incorporated in the Cayman Islands on April 29, 2025, formed to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.
• The company completed its IPO on November 10, 2025, issuing 17,250,000 units at $10.00 per unit, raising gross proceeds of $172,500,000.
• Each unit consists of one Class A ordinary share, one-half of one redeemable warrant exercisable at $11.50, and one right entitling holders to receive 0.20 of a Class A ordinary share upon consummation of a business combination.
• Simultaneously with the IPO, the company sold 375,000 Private Placement Units at $8.00 per unit, generating $3,000,000 in proceeds.
• $172,500,000 of the net proceeds from the IPO and private placement were placed in a Trust Account invested in U.S. government securities or money market funds investing exclusively in U.S. government securities.
• As of December 31, 2025, the Trust Account held $173,403,838, including $903,838 of dividends earned on trust investments.
• The company has 12 months from the IPO closing (November 10, 2026) to complete its initial business combination, extendable to 15 months (February 10, 2027) upon execution of a business combination agreement.
• The company is not engaged in any operations other than searching for a business combination and intends to use cash from the Trust Account, capital stock, debt, or a combination thereof to effectuate the business combination.
• The company must complete a business combination with an aggregate fair market value of at least 80% of the Trust Account value at the time of signing the definitive agreement.
• The company’s management team has extensive experience across technology, financial services, healthcare technology, and consumer businesses, led by Chairman and CEO Prashant Patel.
• The management team has a broad network of relationships across private equity firms, hedge funds, investment banks, family offices, and corporate executives, providing access to proprietary deal flow.
• The company has no full-time employees; management devotes time as necessary to company affairs.
• The company’s liquidity ratios as of June 30, 2026, show current assets of $114,409 and current liabilities of $3,469,896, resulting in a current ratio of 0.03 and a cash ratio of 0, indicating limited liquidity outside the Trust Account.
• The company’s net income for the quarter ended June 30, 2026, was $1,353,765.
• The company’s Class B ordinary shares held by the Sponsor are subject to transfer restrictions until one year after the business combination or other specified conditions.
• The company’s units began separate trading on Nasdaq on or about December 9, 2025, under symbols CRAC (Class A shares), CRACW (warrants), and CRACR (rights).
• The company’s public warrants are exercisable after the later of 30 days post-business combination or 12 months from IPO closing and expire five years after the business combination.
• The company’s risk factors include those disclosed in the 10-K for the period from inception through December 31, 2025, and risks related to the business combination agreement with Carvix, with no material changes as of the latest 10-Q filing.